glp-1 medications market comparison GLP 1 Drug Biosimilar Size and Growth Analysis 2026 to 2035 GLP-1 Drugs Market Size to

Part B covers medically necessary weight loss services for people with a body mass index (BMI) of 30 or higher

Allergic reactions - These rarely occur but can be serious and even life-threatening

Harm reduction allows individuals in higher-weight bodies to receive care without the added external pressure of rigid, weight-centric goals

For heart failure or chronic kidney disease, the American Diabetes Association generally recommends SGLT2 inhibitors as first-line agents, with GLP-1 receptor agonists considered for their benefits on atherosclerotic cardiovascular disease, glycemic control, and weight management, or when SGLT2 inhibitors are not appropriate